You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

mass. movers

Alnylam reports early success with drug

RNA interference (RNAi) technology is used to turn off disease-causing genes.

Globe File photo/2013

RNA interference (RNAi) technology is used to turn off disease-causing genes.

Continue reading below

Alnylam Pharmaceuticals Inc. stock climbed after the Cambridge company reported positive early trial results for an experimental RNA interference drug, ALN-TTRsc. It’s designed to treat transthyretin familial amyloidosis, a rare genetic condition in which a starchy protein builds up in organs and tissues. ALN-TTRsc was evaluated for a form of the disease typically treated with a liver transplant. Alnylam will start a late-stage trial of the drug in 2014. It’s developing the drug in partnership with Genzyme.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com